KDM5B, the histone demethylase which modulates melanoma response to immunotherapy via SETDB1 recruitment and ERV repression, has also been shown to regulate BRAF and MEK inhibitor resistance by controlling a shift between CD34+ and CD34− subpopulations that vary widely in their treatment sensitivities [189]. This evidence concerns the gene CD34 and melanoma.